共 32 条
Expression of programmed death-1 (CD279) in primary cutaneous B-cell lymphomas with correlation to lymphoma entities and biological behaviour
被引:16
作者:
Mitteldorf, C.
[1
]
Bieri, M.
[2
]
Wey, N.
[2
]
Kerl, K.
[3
]
Kamarachev, J.
[3
]
Pfaltz, M.
[4
,5
]
Kutzner, H.
[6
]
Roncador, G.
[7
]
Tomasini, D.
[8
]
Kempf, W.
[3
,5
]
机构:
[1] Klinikum Hildesheim GmbH, Dept Dermatol, Hildesheim, Germany
[2] Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland
[3] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
[4] Univ Zurich Hosp, Dept Psychiat & Psychotherapy, CH-8091 Zurich, Switzerland
[5] Kempf & Pfaltz Histolog Diagnost, Res Unit, CH-8042 Zurich, Switzerland
[6] Dermatopathol Friedrichshafen Bodensee, Friedrichshafen, Germany
[7] Ctr Nacl Invest Oncol, Madrid, Spain
[8] Hosp Busto Arsizio, Dept Dermatol, Busto Arsizio, Italy
关键词:
WHO-EORTC CLASSIFICATION;
REGULATORY T-CELLS;
FOLLICULAR LYMPHOMA;
MYCOSIS-FUNGOIDES;
PD-1;
MARKER;
MICROENVIRONMENT;
LYMPHOCYTES;
CARCINOMA;
BORRELIA;
D O I:
10.1111/bjd.12579
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Background Programmed death-1 (PD-1/CD279) is a cell-surface protein expressed in activated T cells and a subset of T lymphocytes including follicular helper T cells (TFH). The interaction between PD-1 and its ligands plays a role in immune response and evasion of malignancies. In nodal follicular lymphoma, the number of intratumoral PD-1-positive lymphocytes is associated with overall survival. Objectives To investigate 28 cases of primary cutaneous B-cell lymphoma, including the subtypes PCFCL (n=10), PCMZL (n=10) and DLBCL-LT (n=8) for the number and density of PD-1-positive cells. Methods Immunohistochemical staining and a computerized morphometric analysis for evaluation were applied. The results were correlated with the clinical outcome. To distinguish between activated T cells and TFH we performed PD-1/bcl-6 double staining and compared these results with CXCL-13 staining. Double staining for PD-1 and PAX-5 was used to investigate whether tumour cells were positive for PD-1. Results The PD-1-positive cells represented tumour-infiltrating T cells (TILs). Only a minor subset was represented by TFH. Patients with DLBCL-LT had a significantly lower number of PD-1-positive TILs than those with PCMZL (P=0012) and PCFCL (P=0002) or both (P=0001). The difference between PCMZL and PCFCL did not reach significance (P=0074). The tumour cells were negative for PD-1. Conclusions A higher number of PD-1-expressing cells was found in indolent PCMZL and PCFCL than in high-malignant DLBCL-LT. The PD-1-positive cells represented not only TFH, but also other activated T cells as a part of the tumour microenvironment. The tumour cells in all investigated types of PCBCL did not show aberrant PD-1 expression.
引用
收藏
页码:1212 / 1218
页数:7
相关论文